AA
CLDI icon

AQR Arbitrage’s Calidi Biotherapeutics CLDI Stock Holding History

AQR Arbitrage’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-337
Closed -$424K – 796
2023
Q2 		$424K Sell
337
-543
-62% -$675K 0.02% 434
2023
Q1 		$1.08M Hold
880
– – 0.03% 414
2022
Q4 		$1.07M Buy
880
+542
+160% +$649K 0.03% 495
2022
Q3 		$400K Hold
338
– – 0.01% 713
2022
Q2 		$403K Hold
338
– – 0.01% 714
2022
Q1 		$401K Sell
338
-12
-3% -$14.2K 0.01% 641
2021
Q4 		$412K Buy
+350
New +$412K 0.01% 953

Other funds holding CLDI

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $315M AUM 19.93% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

AQR Arbitrage's CLDI Position: Q3 2023 in Review

AQR Arbitrage sold out of Calidi Biotherapeutics (CLDI) in Q3 2023, closing a stake of 337 shares — an estimated $424K sold.

AQR Arbitrage first reported a position in CLDI in Q4 2021 and held it in 7 quarters. The position peaked at $1.08M in Q1 2023. 12 funds tracked by Wall St. Rank hold CLDI as of Q3 2023.

  • AQR Arbitrage reported no remaining Calidi Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • AQR Arbitrage sold 337 Calidi Biotherapeutics shares in Q3 2023, an estimated $424K.
  • AQR Arbitrage first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 7 quarters.
  • AQR Arbitrage's Calidi Biotherapeutics position peaked at $1.08M in Q1 2023.
  • 12 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2023.

Based on AQR Arbitrage's 13F filing for Q3 2023, filed 14 Nov 2023.